ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

FDA Approves Abbott’s HER-2 DNA Probe Kit.

January 25, 2002

Imaging Technique Identifies Consequences Of Mutation

February 24, 2012

Society Growth continues, With OS The Largest; ASCO Plans to Reduce flow Of Medical Oncologists; AACR To Impose Page Charges for “Cancer Research:

May 31, 1985

In Brief: Best Guess On NCI Director: Brown First Choice, Benacerraf Second; FDa On Saccharin

April 22, 1977

Mammography Summit Planned For June In Milan.

March 1, 2002

House Subcommittee Rejects Doubling Budget For Cancer Research, Provides Increase To NIH

July 17, 2009